| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Guanine nucleotide exchange factor-related protein; Deafness locus-associated putative guanine nucleotide exchange factor; DelGEF; |
| Entrez GeneID | 26297; |
| WB Predicted band size | 50kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human SERGEF. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下为3-4条关于SERGEF抗体的示例参考文献(注：内容为虚构示例，仅供格式参考)：
1. **"SERGEF regulates lysosomal exocytosis in macrophages through antibody-targeted functional analysis"**
- **作者**: Chen, L., et al. (2022)
- **摘要**: 本研究利用特异性SERGEF抗体，揭示其在巨噬细胞溶酶体分泌中的关键作用，证实其通过调控钙离子信号影响炎症反应。
2. **"Development of a monoclonal SERGEF antibody for pancreatic cancer biomarker screening"**
- **作者**: Martinez, R., et al. (2021)
- **摘要**: 报道一种高灵敏度SERGEF单克隆抗体的开发，用于检测胰腺癌患者血清中SERGEF蛋白水平，显示其与肿瘤转移正相关。
3. **"SERGEF antibody-based imaging reveals neuronal trafficking defects in Alzheimer's models"**
- **作者**: Kim, S., et al. (2020)
- **摘要**: 通过SERGEF抗体介导的活体成像技术，发现阿尔茨海默病模型中神经元内囊泡运输异常，提示SERGEF可能参与神经退行性病变。
4. **"Structural characterization of SERGEF epitopes using phage display-derived antibodies"**
- **作者**: Gupta, A., et al. (2019)
- **摘要**: 利用噬菌体展示技术筛选SERGEF抗体，解析其结合表位结构，为靶向药物设计提供分子基础。
(提示：实际文献需通过PubMed/Google Scholar以"SERGEF antibody"为关键词检索，并筛选应用或机制相关研究。)
The SERGEF antibody targets the SERGEF protein, also known as TSG101 (tumor susceptibility gene 101), a critical component in cellular processes such as endosomal sorting, membrane trafficking, and viral budding. Initially identified for its role in tumor suppression, TSG101 interacts with the ESCRT (Endosomal Sorting Complex Required for Transport) machinery to regulate the sorting of ubiquitinated proteins into multivesicular bodies (MVBs), influencing lysosomal degradation or exosome release. Dysregulation of SERGEF/TSG101 is implicated in cancer progression, neurodegenerative diseases, and viral pathogenesis (e.g., HIV-1 budding).
The SERGEF antibody is widely used in research to study protein localization, expression levels, and functional interactions via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. Its development has facilitated insights into ESCRT-mediated pathways, autophagy, and extracellular vesicle biogenesis. However, variability in antibody specificity across studies underscores the need for rigorous validation. Researchers often employ SERGEF antibodies to explore its dual roles in tumor suppression and oncogenesis, as well as its potential as a therapeutic target or biomarker in diseases linked to vesicular trafficking defects.
×
